tbuckley/cabot-search huggingface dataset:
France faces radical health insurance reforms
Authors: A. Dorozynski
Journal: BMJ (1995)

The French prime minister, Alain Juppe, received overwhelming support from the National Assembly last week for his plan for a thorough reform of the 50 year old social security system. Deputies voted 463 to 87 to back his project to eliminate the Fr250bn (pounds sterling32bn) debt through a special tax on all incomes, to empower parliament to impose ceilings on welfare spending, and to streamline health administration.

Later in the week the Senate passed a vote of confidence in Mr Juppe, who said that …
TEMPORAL TRENDS AND REGIONAL PATTERNS OF OPERATOR PERCUTANEOUS CORONARY INTERVENTION VOLUME IN THE UNITED STATES: A REPORT FROM THE NCDR CATHPCI REGISTRY
Authors: Alexander C. Fanaroff, Dadi (David) Dai, Matthew Sherwood, Matthew Roe, Tracy Wang, Hitinder Gurm, Mauricio Cohen, John Messenger, Sunil Rao
Journal: Journal of the American College of Cardiology (2016)
Fully covered self-expandable metallic stents with anchor fins: a rose with many thorns
Authors: M. Traina, I. Tarantino, L. Barresi, G. Curcio
Journal: Endoscopy (2011)

We read with interest the study by Phillips et al. [1]. The authors describe their experience with the use of fully covered self-expandable metallic stents (FCSEMS), with anchor fins as an anti-migration system, for the treatment of biliary leaks after liver transplantation.
AB0452 Low-dose interferon alpha-2a treatment in refractory behçet uveitis: a single center experience
Authors: S. G. Yilmaz, G. Keser, Z. Yilmaz, K. Aksu, H. Ates
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To evaluate the efficacy and safety of interferon alpha 2a (IFNa) in the treatment of Behçet patients with severe uveitis resistant and/or intolerant to conventional immunosuppressive (IS) agents such as azathioprine (AZA) and cyclosporine A (CSA). <h3>Methods</h3> This retrospective study included 23 patients with 42 eyes (M/F: 17/6; mean age 31.0±7.9 years) with refractory Behcet uveitis followed up by Ege University Department of Ophtalmology between 2010 and 2012. All the patients fulfilled the international criteria for Behçet’s Disease. According to treatment protocol, induction dose of IFNa were daily 3.0 million IU (MIU) subcutaneously for the first two weeks, while maintenance dose was 3.0 MIU thrice weekly thereafter. In case of relapses, the dose was increased to 6.0 MIU thrice weekly. Visual acuity and yearly uveitis relapse rates were evaluated before and after commencement of IFNa treatment. <h3>Results</h3> Mean time period from the onset of uvetis to commencement of IFNa treatment was 32.6±17.9 months. Previously used AZA and/or CSA were stopped before IFNa treatment was started. While all of the patients responded to induction treatment, relapses occurred in 12 (52.2%) patients during maintenance treatment of 3.0 MIU three times per week. Despite increasing the maintenance dose to 6.0 MIU three times per week, uveitis could not be controlled in half of these patients (n:6), who were later switched to infliximab treatment. In the remaining 17 cases (73.9%), the maintenance treatment with INF was uneventful. Regarding the whole group of patients, mean treatment period with IFNa was 10.9± 5.4 (6-29) months. In 4 patients with remission, IFNa was stopped at the end of one year, and treatment was continued with AZA (2.5 mg/kg/day). While 3 of them remained stable for a mean follow-up period of 8.7±3.1 (6-12) months, only a single case had a uveitis relapse, but responded well to retreatment with IFNa. Considering the 21 eyes of 11 patients who received IFNa treatment longer than one year, basal uveitis relapse rate of 4.2±0.9/year decreased to 1.5±1.4/year (p&lt;0.05). Overall, potential vision was preserved in 36 out of 42 eyes (85.7%) and visual acuity with Snellen was increased at least two lines in 15 eyes (36.6%). As adverse effects, flu-like symptoms were observed in the vast majority of the patients without necessitating interruption of the treatment. However during maintenance period IFNa had to be stopped in 3 patients (13.1%) because of persistent high fever and malaise. <h3>Conclusions</h3> In line with the previous literature data, our results also suggest that IFNa may be an effective and relatively safe option for Behçet uveitis resistant to conventional treatment. <h3>Disclosure of Interest</h3> None Declared
US proposals would require greater disclosure of clinical trial data
Authors: M. McCarthy
Journal: BMJ (2014)

A mentally retarded male patient with a structurally abnormal X chromosome is reported (karyotype 46, dir dup (X)(p11.2 leads to p21.2)Y). In the normal mother a similar X chromosome duplication was found, which was preferentially inactivated. Xg blood groups were studied in the family. The findings indicated that recombination took place at maternal meiosis, as both karyotypically normal sons and the proband were Xg(a-), the mother being Xg(a+). Functional X chromosome disomy may explain clinical abnormalities in reported patients with X duplication and a normal Y chromosome.
Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial
Authors: W Kern, J Braess, A Grote-Metke, H Kuse, R Fuchs, DK Hossfeld, A Reichle, B Wörmann, T Büchner, W Hiddemann
Journal: Leukemia (1998)
KIDNEY DYSFUNCTION IN PATIENTS WITH A SINGLE VENTRICLE FONTAN CIRCULATION
Authors: Alexander R. Opotowsky, Fernando Baraona, Michael Landzberg, Fred Wu, Finnian McCausland, Justin Owumi, Brittani Loukas, Venkata Sabbisetti, Elizabeth Landzberg, Sushrut Waikar
Journal: Journal of the American College of Cardiology (2016)
1219 VX-135, A POTENT SINGLE DIASTEREOMER OF ALS-2200, FOR THE TREATMENT OF CHRONIC HEPATITIS C
Authors: H. Tan, J. Deval, H. Kang, C. Moy, Z. Jin, M. Jiang, A. Ardzinski, R. Rijnbrand, T. Kieffer, L.M. Blatt, S.M. Chanda, N. Dyatkina, G. Wang, Q. Zhang, J.A. Symons, L. Beigelman, D.B. Smith
Journal: Journal of Hepatology (2013)
Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with Hypercholesterolemia
Authors: Henry Buchwald, Richard L. Varco, John P. Matts, John M. Long, Laurie L. Fitch, Gilbert S. Campbell, Malcolm B. Pearce, Albert E. Yellin, W. Allan Edmiston, Robert D. Smink, Henry S. Sawin, Christian T. Campos, Betty J. Hansen, Naip Tuna, James N. Karnegis, Miguel E. Sanmarco, Kurt Amplatz, Wilfredo R. Castaneda-Zuniga, David W. Hunter, Joseph K. Bissett, Frederic J. Weber, James W. Stevenson, Arthur S. Leon, Thomas C. Chalmers
Journal: New England Journal of Medicine (1990)

The Program on the Surgical Control of the Hyperlipidemias (POSCH), a randomized clinical trial, was designed to test whether cholesterol lowering induced by the partial ileal bypass operation would favorably affect overall mortality or mortality due to coronary heart disease. The study population consisted of 838 patients (417 in the control group and 421 in the surgery group), both men (90.7 percent) and women, with an average age of 51 years, who had survived a first myocardial infarction. The mean follow-up period was 9.7 years.
Abstract 1145: Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis
Authors: Kexin Chen, Hanyin Cheng, Lina Zhang, David E. Cogdell, Hong Zheng, Aaron J. Schetter, Matti Nykter, Curtis C. Harris, Stanley R. Hamilton, Wei Zhang
Journal: Cancer Research (2011)

Abstract Background: Colorectal cancer (CRC) remains one of the major cancer types and cancer related death worldwide. Sensitive, non-invasive biomarkers that can facilitate disease detection, staging and prediction of therapeutic outcome are highly desirable to improve survival rate and help to determine optimized treatment for CRC. The small non-coding RNAs, microRNAs (miRNAs), have recently identified as critical regulators for various diseases including cancer and may represent a novel class of cancer biomarkers. The purpose of this study was to identify and validate circulating microRNAs in human plasma for use as such biomarkers. Methodology/Principle Findings: By using quantitative reverse transcription-polymerase chain reaction, we found that circulating miR-141 was significantly associated with stage IV CRC in a cohort of 102 plasma samples. Receiver operating characteristic (ROC) analysis was used to evaluate the sensitivity and specificity of candidate plasma microRNA markers. We observed that combination of miR-141 and carcinoembryonic antigen (CEA), a widely used marker for CRC, further improved the accuracy of detection. These findings were validated in a cohort of 156 plasma samples collected at Tianjin, China. Furthermore, our analysis showed that high levels of plasma miR-141 predicted poor survival in both cohorts and that miR-141 was an independent prognostic factor for advanced CRC. Conclusions/Significance: We propose that plasma miR-141 is a novel biomarker that complements CEA in detecting CRC with distant metastasis and that high levels of miR-141 in plasma were associated with poor prognosis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1145. doi:10.1158/1538-7445.AM2011-1145
Calculation of Renal Differential Function Following Renal Transplant
Authors: Ali M Mansouri, Kaveh Vejdani, Bahar Bastani, Nghi C Nguyen
Journal: Clinical Nuclear Medicine (2012)

The estimation of differential function (DF) in post-renal transplant patients (PRTPs) is challenging because of the different distances of the native kidneys (NKs) and transplant kidney (TK) to the gamma camera and because current commercial software allows evaluation of only 2 kidneys instead of 3. We retrospectively validated a simplified method (SM) to process renal scans and hypothesized that it is comparable with the reference method (RM).Twelve 99mTc MAG3 renal scintigraphies of 10 PRTPs were performed on a dual-head gamma camera. The RM was a 2-step process, with the left and right NKs being compared with the TK separately. The SM was a 1-step process combining both NKs together. The DF estimates were consistent with geometric means in both methods. Statistical evaluation included linear correlation and Bland-Altman analysis.The RM and SM showed DF of 78% ± 25% versus 79% ± 27% for the TK and 22% ± 25% versus 21% ± 27% for the NKs (P = 0.3). There was excellent correlation between SM and RM measurements (r = 0.99, P < 0.001). Bland-Altman plot demonstrated a mean difference of 1.2 ± 3.8 at a 95% confidence interval (95% CI) of agreement of -6.2 to + 8.5 for the TK and -1.2 ± 3.8 at a 95% CI of agreement of -8.5 to + 6.2 for the NKs. Only 1 (8%) of 12 scans showed a difference slightly beyond the 95% CI, indicating a good agreement between SM and RM.The SM offers a simple way to evaluate renal DF in PRTP and shows comparable results with the RM. It may have great potential in clinical practice; however, larger studies are needed to verify and further extend the results of this study.
Abstract 4952: A novel smoothened antagonist, TAK-441, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Authors: Mazyar Ghaffari, Naokazu Ibuki, Irene Iu, Mitali Pandey, Ladan Fazli, Masahide Kashiwagi, Hideaki Tojo, Osamu Nakanishi, Martin E. Gleave, Michael E. Cox
Journal: Cancer Research (2013)

Abstract Hedgehog (Hh) signaling is a highly conserved inter- and intracellular communication mechanism that governs organogenesis and is dysregulated in cancers of numerous tissues, including prostate. Up-regulated expression of the Hh ligands, Sonic (Shh) and Desert (Dhh), has been reported in androgen-deprived and castration-resistant prostate cancer (CRPC). In a cohort of therapy naive, short- and long-term neoadjuvant hormone therapy-treated (NHT), and CRPC specimens, we observed elevated Dhh expression predominantly in long-term NHT specimens and elevated Shh expression predominantly in CRPC specimens. Together with previously demonstrated reciprocal signaling between Shh-producing prostate cancer (PCa) cells and urogenital mesenchymal fibroblasts, these results suggest that castration-induced Hh expression promotes CRPC progression through reciprocal paracrine signaling within the tumor microenvironment. We tested whether the orally available Smoothened (Smo) antagonist, TAK-441, could impair castration-resistant progression of LNCaP PCa xenografts by disrupting paracrine Hh signaling. While TAK-441 or cyclopamine did not affect androgen withdrawal-induced Shh up-regulation or viability of LNCaP cells, castration-resistant progression of LNCaP xenografts was significantly delayed in animals treated with TAK-441. In TAK-441-treated xenografts, expression of murine orthologues of the Hh-activated genes, Gli1, Gli2, and Ptch1, was substantially suppressed, while expression of the corresponding human orthologues was unaffected. Since androgen-deprived LNCaP cells up-regulate Shh expression, but are not sensitive to Smo antagonists, these studies indicate that TAK-441 leads to delayed castration-resistant progression of LNCaP xenografts by disrupting paracrine Hh signaling with the tumor stroma. Thus, paracrine Hh signaling may offer unique opportunities for prognostic biomarker development, drug targeting and therapeutic response monitoring of PCa progression. Citation Format: Mazyar Ghaffari, Naokazu Ibuki, Irene Iu, Mitali Pandey, Ladan Fazli, Masahide Kashiwagi, Hideaki Tojo, Osamu Nakanishi, Martin E. Gleave, Michael E. Cox. A novel smoothened antagonist, TAK-441, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4952. doi:10.1158/1538-7445.AM2013-4952
OUTCOMES AND PREDICTORS OF MORTALITY IN NON-RHEUMATIC PATIENTS WITH MITRAL ANNULAR CALCIFICATION AND MITRAL REGURGITATION
Authors: Karan Sud, Akhil Parashar, Shikhar Agarwal, Amar Krishnaswamy, William Stewart, Leonardo Rodriguez, E. Murat Tuzcu, Samir Kapadia
Journal: Journal of the American College of Cardiology (2016)
A case of endoscopic necrosectomy after transgastric EUS-guided drainarge of pancreatic pseudocyst
Authors: H Ishikawa, K Yamao, S Okamura, A Itho, Y HIrooka, H Goto
Journal: Endoscopy (2006)

A 49 year-old man with pancreatic pseudocyst after severe acute pancreatitis was hospitalized due to an abdominal pain with the increased pancreatic pseudocyst on October 8, 2004. Abdominal CT on admission showed the giant pancreatic pseudocyst more than 15cm in diameter. EUS-guided fine needle aspiration (FNA) was performed to the pancreatic pseudocyst by transgastric route, using 19G needle (Wilson-Cook) with linear array echoendoscopes. We inserted guide wire (0.035 inch) into the pseudocyst and placed 7Fr pig tail type nasocystic drain into the pseudocyst, and the size of the pseudocyst was slightly reduced. Irrigation of pseudocyst with physiological saline and injection of antibiotics into the pseudocyst were performed, because methicillin resistant staphylococcus aureus and gram negative rod were detected from the culture of the contents. Despite of these treatments, the size of the pseudocyst was not decreased and remittent fever was continued, multiple pigtail stents were placed from the gastric wall into the pseudocyst after balloon dilatation on November 16, 2004, and a few days after the endoprosthesis, endoscopic necrosectomy was done endoscopically using baskets and forceps. After total nine times of endoscopic necrosectomy, the pancreatic pseudocyst (pancreatic abscess) was successfully treated. The patient discharged on December 23, 2004, and no sign of recurrence was observed during 17 months. We experienced a successful case of endoscopic necrosectomy after transgastric EUS-guided drainarge of pancreatic pseudocyst.
SAT0333 Inhibitor of Interleukin-1 in the Complex Treatment of Secondary Osteoarthritis of the Knee in Patients with Rheumatoid Arthritis
Authors: I. Starodubtseva, L. Vasilieva, N. Barsukova
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Diseases that cause inflammation such as rheumatoid arthritis (RA) can increase the risk of development of secondary osteoarthritis (OA). In the treatment of patients with RA no attention is paid to treatment of associate secondary OA. <h3>Objectives</h3> The aim of the study was to estimate the efficacy of therapeutic approach with the use of inhibitor of interleukin-1 in the complex therapy of secondary OA of the knee in patients with RA. <h3>Methods</h3> 150 patients (139 females and 11 mails) with secondary OA of the knee in RA were enrolled in the trial (mean age 56,5±12,2) with the duration of the disease 5-15 years). All of them had the definite diagnosis RA according to the criteria of ACR/EULAR. Patients were divided into 2 groups. 75 patients (group 1) underwent complex drug therapy (methotrexate (MTX) 10-15 mg per week and inhibitor of interleukin-1 (IL-1) (diacerein in doses 50 mg 2 times per day). 75 patients (group 2) received only basic treatment (MTX 10-15 mg per week). We evaluated joint pain on 100-mm visual analog scale (VAS), indexes WOMAC, Lequesne, Diseases Activity Score (DAS28), Health Assessment Questionnaire (HAQ) before treatment and after 6 months. <h3>Results</h3> 10 patients discontinued the treatment due of diarrhea in two weeks after the beginning of therapy with the use of diacerein. The results of the trial (in group 1) showed the significant reduction of joint pain on VAS (68,7±1,82 mm vs. 39,4±1,76 mm, p&lt;0,001), WOMAC (126,4±2,77 vs 76,2±1,98 p&lt;0,001), Lequesne (12,6±0,32 vs 9,1±0,33 p&lt;0,001), HAQ (1,16±0,44 vs. 0,81±0,48 p&lt;0,05), DAS28 (3,45±1,18 vs. 1,96±1,22, p&lt;0,05). According to the findings of group 2, it was statistically significant reduce of all indicators. But the comparative analysis of the results in two groups revealed statistically significant differences between groups for most parameters for the benefit of group 1. <h3>Conclusions</h3> The therapeutic approach with the use of inhibitor of interleukin-1 in the complex therapy of secondary OA of the knee in RA in comparison with traditional drug therapy is significantly more effective not only in the treatment of coexisting pathology (secondary OA), but and basic disease (RA). <h3>Disclosure of Interest</h3> None Declared
RISK STRATIFICATION FOR SUDDEN CARDIAC DEATH IN PATIENTS WITH HEART FAILURE: ROLE FOR 123-IODINE METAIODOBENZYLGUANIDINE IMAGING AND CARDIAC MAGNETIC RESONANCE IMAGING. A REAL WORLD SINGLE CENTRE EXPERIENCE
Authors: Paolo Severino, Simone Calcagno, Andrea Ceccacci, Maria Lembo, Alessandra Cinque, Nicolo’ Salvi, Viviana Maestrini, Massimo Mancone, Francesco Fedele
Journal: Journal of the American College of Cardiology (2015)
Difficulty in determining the depth of cancer invasion by EUS for wide-spreading superficial squamous cell cancer of the esophagus
Authors: T Hirano
Journal: Endoscopy (2006)

[Aims] The depth of invasion of squamous cell carcinoma of the esophagus (SCCE) is very important because it is highly related to the incidence of lymph node metastasis and patient prognosis. EUS is known to be useful to determine the depth of cancer and staging in SCCE. Wide-spreading superficial SCCE is defined as mucosal and/or submucosal cancer larger than 5cm without an apparent elevated or depressed area in the lesion. This type of SCCE is known to be difficult both in detection and in determining the depth of cancer by radiological and endoscopic examinations. We report EUS findings of three cases. [Patients and methods] All the patients were male with their age ranging from 61 to 75 years. The lesions were found by endoscopy (EGD). EUS (EU-M30 and miniature probe 20 and/or 30MHz, Olympus, Tokyo, Japan) was applied. [Results] The maximum lengths of the lesions were 5 to 10cm. Endoscopic findings at detection included abnormal vascular patterns and slight changes of the surface. Iodine staining clearly showed the cancerous lesions. On EUS, no abnormalities were found in two cases where cancerous lesions could not be visualized because of the thin cancerous layer. In one case, EUS showed a thickened low echoic cancer area mostly limited to mucosal layer and a tiny low echoic area in the fifth layer of 9 layer structure, suggesting a submucosal involvement. Two cases received subtotal esophagectomy, and one of these showed a histological submucosal cancer invasion (178 micro-meter in depth) with lymph node metastases. In the other case, the cancer was limited to the shallow mucosal layer without lymph node metastasis. The other patient received radio-chemotherapy. [Conclusions] In wide-spreading superficial SCCE, determination of the depth of cancer invasion is still difficult even using EUS because the lesion is too wide to observe the whole cancerous area.
Abstract LB-432: Effect of chronic nicotine consumption on NNK-induced lung tumors in the A/J mouse
Authors: Sharon E. Murphy, Linda B. von Weymarn, Melissa M. Schutten, Mitzi Lewellen, Fekadu Kassie, Jaime F. Modiano
Journal: Cancer Research (2011)

Abstract Nicotine replacement therapy (NRT) is often used to maintain smoking cessation. Some individuals continue to use NRT for years after smoking cessation, and some NRT users continue to smoke. It is important to understand the impact of chronic nicotine use on lung cancer risk. Therefore, we determined the effect of nicotine administration on NNK-induced lung tumors in the A/J mice. P450 2A enzymes are key catalysts in NNK bioactivation, and nicotine is both an inhibitor and a mechanism based inactivator of P450 2A-catalyzed nicotine metabolism. These data suggest nicotine might protect from NNK-induced tumorigenesis. However, several investigators have reported that nicotine inhibits apoptosis, enhances angiogenesis and enhances proliferation. We hypothesized that nicotine would prevent or delay initiation of NNK-induced tumors, but accelerate tumor growth by reducing apoptosis and promoting inflammation. To test this, female A/J mice were administered a single dose of NNK (100 mg/kg i.p) and 200 ug/ml nicotine in the drinking water. Nicotine was administered 2 weeks prior to NNK, 44 weeks after NNK, throughout the experiment, or without NNK treatment. There were several key outcomes of this study: Chronic nicotine consumption did not affect P450 2A5-catalyzed metabolism in the lung of liver. Nicotine administration alone for 44 weeks did not increase lung tumor multiplicity. Nicotine given before or after NNK administration did not increase, or decrease, tumor number or tumor size. There was also no difference in the number of carcinomas per mouse or the number of adenomas with dysplasia. In conclusion, nicotine consumption in the drinking water had no effect on the tumorigenicity of NNK in the A/J mouse. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-432. doi:10.1158/1538-7445.AM2011-LB-432